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Aim Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart failure with reduced ejection fraction
(HFrEF), but are underutilized. Hyperkalaemia may be one reason, but the underlying reasons for underuse are
unknown. The aim of this study was to investigate the independent predictors of MRA underuse in a large and
unselected HFrEF cohort.
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Methods
and results
We included patients with HFrEF (ejection fraction <40%), New York Heart Association (NYHA) class II–IV
and heart failure (HF) duration ≥6 months from the Swedish HF Registry. Logistic regression analysis identified
independent associations between 39 demographic, clinical, co-treatment, and socioeconomic predictors and MRA
non-use. Of 11 215 patients, 27% were women; mean age was 75± 11 years; only 4443 (40%) patients received
MRA. Selected characteristics independently associated with MRA non-use were in descending order of magnitude:
lower creatinine clearance (<60 mL/min), no need for diuretics, no cardiac resynchronization therapy/implantable
cardioverter-defibrillator, higher blood pressure, no digoxin use, higher ejection fraction, outpatient setting, older
age, lower income, ischaemic heart disease, male sex, follow-up in primary vs. specialty care, lower NYHA class, and
absence of hypertension diagnosis. Plasma potassium and N-terminal pro B-type natriuretic peptide levels were not
associated with MRA non-use.
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Conclusion Mineralocorticoid receptor antagonists remain underused in HFrEF. Their use does not decrease with elevated
potassium but does with impaired renal function, even in the creatinine clearance 30–59.9 mL/min range where
MRAs are not contraindicated. MRA underuse may be further related to non-specialist care, milder HF and no use
of other HF therapy.
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Introduction
Mineralocorticoid receptor antagonists (MRAs; spironolactone
and eplerenone) reduce mortality and morbidity in patients with
New York Heart Association (NYHA) class II–IV heart failure
with reduced ejection fraction (HFrEF)1,2 and received class IA
recommendation in guidelines.3,4 However, MRAs are underused
in the USA5 and Europe.6,7 Hyperkalaemia and worsening renal
function have been addressed as potential explanations for this
phenomenon,8 although importantly their occurrence does not
reduce the benefit of MRAs.9,10 Furthermore, the independent
underlying reasons for MRA underuse in the real world are
unknown.
The aim was to measure MRA non-use/use in a large unselected
cohort of HFrEF patients, and to investigate the independent
associations with MRA non-use.
Methods
Study protocol and setting
The Swedish Heart Failure Registry (SwedeHF; www.SwedeHF.se)
has been previously described.11 The only inclusion criterion is
clinician-judged heart failure (HF). Approximately 80 variables are
recorded at discharge from hospital or after an outpatient clinic visit
on a web-based case report form and entered into a database man-
aged by the Uppsala Clinical Research Center, Uppsala, Sweden (www
.UCR.UU.se). The protocol, case report form and annual reports are
available at www.SwedeHF.se.
The Swedish Board of Health and Welfare (www.socialstyrel-
sen.se) administers the Patient Registry that provided additional
baseline co-morbidities, defined according to ICD-10 codes. ICD-10
coding in Sweden has been validated, with a positive predictive value
ranging between 85% and 95% for most diagnoses.12 Statistics Sweden
(www.scb.se) provided socioeconomic characteristics. Recording of
ICD codes and socioeconomic data occurs with a lag time and the
procedures around linking to SwedeHF take time. Therefore, this
study included SwedeHF registrations between 11 May 2000 (start of
SwedeHF) and 31 December 2012, ensuring that all linked ICD code
and socioeconomic data up to this date were available.
All Swedish citizens have unique personal identification numbers
that allow linking of disease-specific health registries and governmental
health and statistical registries.
Establishment of the HF registry and this analysis with linking of
the above registries were approved by a multisite ethics committee.
Individual patient consent was not required, but patients were informed
of entry into national registries and allowed to opt out.
In SwedeHF, ejection fraction (EF) is categorized as <30%, 30–39%,
40–49%, and≥ 50%. We included <30% and 30–39%. MRAs are indi-
cated with symptoms, so NYHA class II–IV patients were included.
MRAs were proven effective in NYHA class III–IV HFrEF in RALES in
19992 and in NYHA class II HFrEF in EMPHASIS-HF in 2011.1 Thus,
a consistency analysis including NYHA class III–IV from 2000 (start of
the registry) and NYHA class II–IV from 2012 (when EMPHASIS-HF
had been published and had time to penetrate the HF community)
was performed. Patients with creatinine clearance <30 mL/min or
K> 5.0 mEq/L were excluded from trials and do not have MRA indica-
tion. In the real world, many patients fluctuate around these cut-offs.
If patients are already treated (which many may have been prior



















































































.. hyperkalaemia unless very severe is not a reason to discontinue MRAs.3
Therefore, the main analysis included the few patients with creati-
nine clearance <30 mL/min or K> 5.0 mEq/L, but a consistency analy-
sis was also performed excluding these patients. MRAs are third-line
therapy in HFrEF, so patients with HF duration ≥6 months were
included to ensure adequate time for initiation of MRA therapy.
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
(ACE-I/ARB) use was considered as a yes/no variable, but in order to
evaluate the possibility that sub-target dosing of ACE-I/ARB may be
a reason for MRA non-use, an additional consistency analysis was per-
formed where ACE-I/ARB use was classified as target dose of ACE-I or
ARB or use of both ACE-I and ARB vs. non-use or non-target dose of
ACE-I or ARB. Registrations with missing data for MRA use, EF, NYHA
class and HF duration were excluded.
Statistical analysis
Baseline characteristics
Baseline characteristics of patients receiving vs. not receiving MRA
were compared by t-test or Wilcoxon–Mann–Whitney to test con-
tinuous variables, and by chi-squared to test categorical variables. In
a registry setting, patients may have missing baseline data. Excluding
these patients from multivariable analyses would introduce bias due
to the fact that baseline data are not completely missing at random.
Therefore, missing data were managed by multiple imputation using
chained equations method (n= 10). All analyses, except for descriptive
statistics, were performed on imputed data.
Predictors of mineralocorticoid receptor antagonist
non-use
In order to identify the independent predictors of MRA non-use,
multivariable logistic regression models were performed using MRA
non-use as dependent variable. Because predictors of MRA non-use
are presently unknown and since the sample size was sufficiently large,
we did not perform any stepwise variable selection procedure for
choosing the variables to include in multivariable models. Instead, we
included all variables from SwedeHF, the Patient Registry, and Statistics
Sweden, which were clinically relevant and deemed potentially relevant
in directly or indirectly affecting the decision to use MRAs. These added
up to 39, marked with an asterisk in Table 1. Additional variables were
either related and covarying (e.g. creatinine and creatinine clearance,
weight and body mass index, etc.) or not deemed relevant, and
therefore not included in the model.
Statistical analyses were performed by Stata 14.2 (Stata Corp LLC,
College Station, TX, USA). A P-value of <0.05 was considered statis-
tically significant.
Results
Between 11 May 2000 (start of SwedeHF) and 31 December
2012, 80 772 registrations were recorded from 51 060 unique
patients. Of these, 11 215 were patients with HFrEF, NYHA class
II–IV and HF duration ≥6 months who reported no missing data
for MRA use; 4443 (40%) patients were receiving MRA and 6772
(60%) were not (Figure 1).
Baseline characteristics
In the overall population, the mean age was 75±11 years,
27% were woman. There were numerous differences between
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Table 1 Baseline characteristics
Variables MRA No (n= 6772, 60%) MRA Yes (n= 4443, 40%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Gendera, n (%) 0.085
Male 4932 (72.8) 3301 (74.3)
Female 1840 (27.2) 1142 (25.7)
Agea, years, mean (SD) 74.4 (11.1) 71.9 (11.2) <0.001
Registration yeara, n (%) <0.001
2000–2008 3330 (49.2) 2385 (53.7)
2009–2012 3442 (50.8) 2058 (46.3)
Specialtya, n (%) 0.025
Internal Medicine or Geriatrics 2892 (44.3) 1818 (42.2)
Cardiology 3631 (55.7) 2494 (57.8)
Caregivera, n (%) 0.005
Inpatient 3141 (46.4) 2181 (49.1)
Outpatient 3631 (53.6) 2262 (50.9)
Follow-up referral specialtya, n (%) <0.001
Cardiology or Internal Medicine 4098 (65.6) 2978 (71.5)
Primary or other care 2151 (34.4) 1189 (28.5)
Follow-up referral to outpatient HF nurse clinica, n (%) 2597 (41.5) 1780 (42.9) 0.17
Clinical variables
NYHA classa, n (%) <0.001
II 2958 (43.7) 1731 (39.0)
III 3308 (48.8) 2392 (53.8)
IV 506 (7.5) 320 (7.2)
Left ventricular ejection fractiona, n (%) <0.001
30–39% 3451 (51.0) 1781 (40.1)
<30% 3321 (49.0) 2662 (59.9)
Body mass indexa, kg/m2, mean (SD) 26.4 (5.0) 27.0 (5.5) <0.001
Systolic blood pressure, mmHg, mean (SD) 124.2 (20.5) 119.0 (19.5) <0.001
Diastolic blood pressure, mmHg, mean (SD) 72.3 (11.7) 70.7 (11.5) <0.001
Mean arterial pressurea, mmHg, mean (SD) 89.6 (12.9) 86.8 (12.5) <0.001
Heart ratea, b.p.m., mean (SD) 73.2 (14.9) 72.5 (14.0) 0.011
Laboratory values
Creatinine clearance, mL/min, mean (SD) 58.3 (30.6) 65.5 (31.7) <0.001
Creatinine clearancea, n (%) <0.001
<30 mL/min 991 (15.7) 353 (8.4)
30–59.9 mL/min 2798 (44.3) 1807 (42.7)
≥60 mL/min 2526 (40.0) 2070 (48.9)
Potassium, mEq/L, mean (SD) 4.2 (0.5) 4.2 (0.5) 0.89
Potassiuma, n (%) 0.649
<3.5 mEq/L 167 (4.1) 113 (4.5)
3.5–5 mEq/L 3756 (91.8) 2283 (91.2)
>5.0 mEq/L 166 (4.1) 106 (4.3)
Haemoglobin, g/L, mean (SD) 132.0 (17.1) 133.6 (16.9) <0.001
NT-proBNPa, pg/mL, median (IQR) 3197.0 (1318.5–7614.0) 3039.5 (1320.0–7200.0) 0.41
Co-morbidities, n (%)
Smokinga 0.72
Never 2121 (39.2) 1400 (38.6)
Previous 2603 (48.1) 1774 (48.9)
Current 691 (12.8) 452 (12.5)
Hypertensiona 4039 (59.6) 2614 (58.8) 0.39
Diabetes mellitusa 2104 (31.1) 1533 (34.5) <0.001
Ischaemic heart diseasea 4527 (68.9) 2830 (65.3) <0.001
Coronary revascularizationa 2684 (39.6) 1753 (39.5) 0.85
Peripheral artery diseasea 874 (12.9) 519 (11.7) 0.054
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Table 1 Continued
Variables MRA No (n= 6772, 60%) MRA Yes (n= 4443, 40%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stroke/transient ischaemic attacka 1277 (18.9) 767 (17.3) 0.032
Atrial fibrillationa 3871 (57.2) 2648 (59.6) 0.010
Anaemiaa,b 2526 (37.3) 1530 (34.4) 0.002
Valvular heart diseasea 1793 (27.1) 1214 (27.9) 0.34
Lung diseasea 1878 (27.7) 1268 (28.5) 0.35
Concomitant medications, n (%)
ACE-I or ARBa 5913 (87.5) 4016 (90.6) <0.001
ACE-I or ARBc <0.001
None or< target dose 4361 (64.7) 2333 (52.7)
≥ target dose or ACE-I+ARB 2378 (35.3) 2096 (47.3)
Digoxina 1092 (16.1) 1063 (24.0) <0.001
Diuretica 5599 (82.8) 4012 (90.5) <0.001
Nitratea 1463 (21.7) 854 (19.3) 0.002
Platelet inhibitora 3626 (53.7) 2153 (48.6) <0.001
Oral anticoagulanta 2685 (39.8) 2121 (47.9) <0.001
Statina 3442 (51.0) 2305 (52.0) 0.29
Beta-blockera 6030 (89.1) 4041 (91.1) <0.001
Heart failure devicesa <0.001
None 6113 (91.0) 3736 (84.6)
CRT-P 199 (3.0) 209 (4.7)
CRT-D 170 (2.5) 220 (5.0)
ICD 235 (3.5) 250 (5.7)
Socioeconomic variables
Family typea, n (%) 0.86
Living alone 3269 (48.4) 2135 (48.2)
Married/cohabitating 3492 (51.6) 2296 (51.8)
Educationa, n (%) 0.012
Compulsory school 3329 (49.7) 2062 (46.9)
Secondary school 2481 (37.1) 1700 (38.7)
University 882 (13.2) 630 (14.3)
Incomea, below median, n (%) 3487 (51.7) 2092 (47.3) <0.001
Number of childrena, mean (SD) 2.0 (1.4) 2.0 (1.4) 0.093
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization
therapy-pacemaker; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart
Association; SD, standard deviation.
aVariables included in the multivariable logistic regression model.
bAnaemia was defined according to haemoglobin levels (<120 g/L in women and<130 g/L in men).
cIncluded in the consistency analysis. Registration year was included as a continuous variable in the multivariable models.
untreated vs. treated patients, including higher age, more care in
and follow-up referral to internal medicine, geriatrics, or primary
care vs. cardiology. Notably, potassium and N-terminal pro B-type
natriuretic peptide (NT-proBNP) levels were similar in those using
and not using MRA. Untreated patients also received less ACE-I or
ARB, digoxin, diuretics, oral anticoagulants, beta-blockers and HF





The differences in Table 1 are unadjusted and may represent






















.. odds ratios (ORs) for MRA non-use after multivariable logistic
regression are shown in descending order of magnitude in Figure 2,
and included e.g. lower creatinine clearance (<30 mL/min but
also 30–59.9 mL/min was associated with non-use), no use of
diuretics, no cardiac resynchronization therapy (CRT)/implantable
cardioverter-defibrillator (ICD), higher blood pressure, higher
EF, outpatient setting, older age, lower income, ischaemic heart
disease, male sex, lower NYHA class, follow-up in primary care
vs. cardiology/internal medicine, absence of hypertension diagnosis
and later year of registration. Plasma potassium and NT-proBNP
were not associated with MRA non-use. Non-use of digoxin
remained associated with MRA non-use, whereas non-use of
beta-blockers only approximated a statistically significance, and
no association was reported between ACE-I/ARB use and other
treatment use (nitrates, platelet inhibitors and statins) and MRA
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Figure 1 Flow chart of patient selection. EF, ejection fraction; HF, heart failure; MRA, mineralocorticoid receptor antagonist; NYHA, New
York Heart Association.
non-use. However, when doses of ACE-I/ARB were considered and
ACE-I/ARB use was categorized as at (or above) target dose or use
of both ACE-I and ARB vs. no use or sub-target dose (target doses
for ACE-I and ARB are reported in the supplementary material
online, Table S1), sub-target doses or no use was significantly
associated with MRA non-use (OR 1.61; 95% CI 1.48–1.75)
(Figure 2).
Other clinical variables/co-morbidities not associated with
MRA non-use were body mass index, smoking, history of
stroke/transient ischaemic attack, diabetes, lung disease, valvu-
lar disease, heart rate, atrial fibrillation, peripheral artery
disease, previous coronary revascularization, and anaemia. Demo-
graphic/organizational variables not associated with MRA non-use
were number of children, education level, living alone vs. being
married/cohabitating, being registered in cardiology vs. internal
medicine/geriatrics departments, and having a planned follow-up
in a HF nurse-led clinic.
Consistency analysis
In the consistency analysis including patients in NYHA class II
enrolled from 2012 only plus all the patients in NYHA class III–IV,
2939 (41%) received MRAs and 4177 (59%) did not. All the find-
ings observed in the main analysis were confirmed except for
NYHA class and hypertension that were not significantly associ-
ated with MRA non-use. We also repeated the analyses exclud-
ing patients with creatinine clearance <30 mL/min or missing and
K> 5.0 mEq/L or missing. In this cohort, 2123 patients (40%)
received MRAs and 3141 (60%) did not. As compared with the













































.. rate≥ 70 vs. <70 b.p.m., being registered in cardiology vs. internal
medicine/geriatrics departments and higher number of children,
whereas ischaemic heart disease, gender, age and year of regis-
tration were not associated with MRA non-use (supplementary
material online, Figure S1).
Discussion
In the large and unselected nationwide SwedeHF, we observed that
only 40% of patients with HFrEF, NYHA class ≥II and HF duration
≥6 months received MRA and that low creatinine clearance was a
dominant risk factor for MRA non-use, even in the creatinine clear-
ance 30–59.9 mL/min range where MRAs are not contraindicated.
Furthermore, MRA use did not decrease with elevated potassium
levels. MRA underuse might be further linked to non-specialist
care, no use or sub-optimal dosing of ACE-I/ARB, milder HF, and
perceived rather than actual risk of hyperkalaemia.
Underuse of mineralocorticoid receptor
antagonists in heart failure with reduced
ejection fraction patients
The MRA underuse observed in the present study confirms
previous analyses (Table 2).5,7,13–16 In the US Get With The
Guidelines-HF quality improvement registry, only 32% of eligible
patients received MRAs between 2005 and 2007, but a trend
towards an increase in prescription over time was observed.5
Similarly, an analysis from the Registry to Improve the Use of
Evidence-Based Heart Failure Therapies in the Outpatient Setting
(IMPROVE HF) reported 36% of the eligible population treated
© 2018 The Authors
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Figure 2 Independent predictors of mineralocorticoid receptor antagonist (MRA) non-use. CI, confidence interval; CRT-D, cardiac
resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; ICD, implantable cardioverter-defibrillator;
NYHA, New York Heart Association; OR, odds ratio.
by MRA.13 In Europe, the EuroHeart Failure Survey II showed
that 47.5% of patients discharged after a hospital admission for
new-onset or decompensated HF received MRAs,14 whereas in the
European Society of Cardiology (ESC) HF pilot survey the rates







. More recently, in the BIOSTAT-CHF programme enrolling patients
with new-onset or worsening of HF who had not been previously
treated with evidence-based therapies, 56% and 63% of eligible
patients received MRA before and after HF treatment optimiza-
tion, respectively,7 whereas in the ESC HF Long-Term Registry
© 2018 The Authors
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Table 2 Summary of current evidence on mineralocorticoid receptor antagonist underuse in heart failure with
reduced ejection fraction
Study MRA use
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GWTG-HF5 32% of the eligible population.
IMPROVE HF13 36% of the eligible population.
EuroHeart Failure Survey II14 47.5% of patients discharged after a hospital admission for HF.
ESC-HF Pilot Survey15 ∼50% in inpatients at discharge and 44% in outpatients.
BIOSTAT-CHF7 56% of eligible patients before and 63% after HF treatment optimization.
ESC-HF-LT16 53.9% of patients hospitalized for acute HF received MRA at discharge and 56.5% at 1 year from hospitalization.
SwedeHF (current study) 40% of the eligible population.
HF, heart failure; MRA, mineralocorticoid receptor antagonist.
(ESC-HF-LT) 53.9% of patients hospitalized for acute HF received
MRA at discharge and 56.5% at 1 year from hospitalization.16,17
Even when not considering MRAs indicated in NYHA class II until
2012, only 41% received MRAs in the present study. Similarly, when
patients with K> 5.0 mEq/L and creatinine clearance <30 mL/min
were excluded, again only 40% received MRAs. A previous analysis
of SwedeHF has shown high utilization of renin–angiotensin sys-
tem antagonists and beta-blockers that were prescribed in more
than 90% of the population, but modest use of MRA that even
decreased over time, from 53% in 2003 to 42% in 2012.6 However,
a major limitation of previous analyses is absence of explanatory
factors. Therefore, a common assumption has simply addressed




Notably, in the present study, plasma potassium levels at baseline
were not associated with MRA use decisions at baseline. The
cause and effect relationship is of course difficult to establish,
but hypokalaemia is likely a reason for use, and hyperkalaemia
both a reason for non-use and a consequence of use. However,
chronic kidney disease was a strong predictor of MRA non-use,
with both creatinine clearance<30 and 30–59.9 mL/min associated
with underuse. Creatinine clearance <30 mL/min associated with
MRA non-use is expected since MRAs are contraindicated in
severe renal disease. However, MRAs are not contraindicated and
have been shown to be effective in reducing the risk of all-cause
death, cardiovascular death and HF hospitalization in patients with
estimated glomerular filtration rate 30–59.9 mL/min/1.73 m2,18
thus MRA underuse reported by our analysis in this subgroup is not
justified. Similarly, we reported underuse in patients aged >75 years
but MRAs have previously been shown to be equally effective also
in the elderly.18 These findings may suggest that a perceived risk
of worsening renal function may have a role in MRA non-use.
Relatedly, diuretic use was the strongest independent predictor of
MRA use. One potential explanation for this observation could be
that MRAs and loop diuretics were used to balance potassium levels
and also in more severe HF. Hypertension was associated with





























































. suggesting but not proving that MRAs have been used and/or
tolerated in patients with hypertension, but also have been effective
in lowering blood pressure, resulting in lower blood pressure in
treated patients. When ACE-I/ARB use was analysed as a yes/no
variable, it was not associated with MRA use. However, no use
or sub-target dosing of ACE-I/ARB (a larger group than simply
non-use) was significantly associated with MRA non-use, which
could be explained by similar factors influencing both the choice
of MRA non-use and of prescribing no or underdosed ACE-I/ARB
(i.e. fear for worsening renal function). Furthermore, non-use, or
importantly, failure to reach target doses of ACE-I/ARB (whether
fully attempted or not), appears to lead to non-use of MRA.
Finally, no referral to cardiology specialists and no use of other
HF treatments, as well as lower income were together important
associations with MRA non-use, suggesting that organizational,
logistical and access to care issues may be relevant, similarly as
for other HF interventions.19,20 Indeed, a willingness and ability to
undergo follow-up and monitoring is a requirement for MRAs (and
other HF therapy) and although we cannot assess this willingness
per se, many of the variables assessed may be indirect markers of
low willingness or ability to undergo follow-up.
Limitations
Because of the cross-sectional nature of this study, for many
associations described, cause and effect relationships cannot be
established. We cannot rule out potential effects of unmeasured
confounders affecting MRA non-use. We included patients enrolled
in the SwedeHF between 2000 and 2012, thus, we cannot exclude
any potential improvement in MRA prescriptions following the
EMPHASIS-HF trial publication in 20111 and the consequent
implementation of guidelines. We did not have access to type
of MRA, but overall in Sweden, >98% of MRAs prescribed and
dispensed are spironolactone.21 Generalizability of our findings
to other countries depends on similarities in population char-
acteristics, health care and HF management. Finally, longitudinal
data and time relationship between clinical variables, particularly
previous measures of serum potassium levels that might have
influenced decisions on whether or not to start an MRA, and med-
ication use represent a major limitation of this and other registry
studies.
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Conclusions
There are still signals of MRA underuse in HFrEF. Reduced
renal function, even in the 30–59.9 mL/min range, was associ-
ated with MRA underuse, but elevated potassium levels were not.
Thus, we emphasize that the ESC HF guidelines recommend that
while estimated glomerular filtration rate< 30 mL/min/1.73 m2 or
K> 5.0 mEq/L are contraindications to MRA initiation, for patients
already treated with MRAs, renal function and K need to be con-
siderably worse in order to consider dose reduction or discontin-
uation of MRAs.3
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